Ottawa-Shanghai Joint School of Medicine


XIAO Xiuying

chief physician


Tel: 021-68385559

Research Fields: 胃肠道肿瘤的发生和转移机制及新药临床研究

Personal Information

  • Chief physician, Master Supervisor, Deputy Director of Oncology Department, Renji Hospital, School of Medicine, Shanghai Jiaotong University

  • Member of gastric Cancer Professional Committee of Chinese Society of Clinical Oncology (CSCO), Member and Secretary of Oncology Branch of Shanghai Medical Association and Deputy head of Gastroenterology Group, Member of the expert Committee of Shanghai Cancer chemotherapy Quality Control Center, Youth Director of Shanghai Anti-Cancer Association, Member of Digestive tract Oncology Committee of Chinese Research Hospital Association, etc.

EDUCATION Background

  • 1995.9~2000.7  Bachelor (Clinical Medicine), Shanxi Medical University, China

  • 2003.9~2006.7  Master of Medicine (Oncology), Cancer Hospital, Fudan University, China

  • 2009.9~2012.6  M.D., Ph.D. (Oncology), Cancer Hospital, Fudan University, China


  • 2000.7~2006.7    Resident in Department of Pathology, Heibei North University, Zhangjiakou, Hebei, China

  • 2004.2~2004.7    Lecturer, Department of Pathology, Shanghai Medical College, Fudan University, China

  • 2006.7~2012.12   Attending physician, Vice-director, Department of Oncology, Shanghai Xuhui District Central Hospital, Shanghai, China

  • 2013.1~2019.12   Deputy Chief Physician, Department of Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

  • 2020.1~present   Chief Physician, Department of Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China


  • Mechanism of occurrence and Metastasis of Gastrointestinal tumors

  • Clinical study of anti-Cancer New drugs

Clinical research

  1. Phase III, randomized, open clinical trial comparing Pembrolizumab (MK-3475) and paclitaxel in subjects with advanced gastric or gastroesophageal junction adenocarcinoma who progressed after first-line platinum combined with fluorouracil treatment. MSD Pharmaceuticals Ltd,Participate, Participated, finished.

  2. A randomized, open, international multi-center, phase III clinical trial of GB201 combined with FOLFIRI compared with GB201 in patients with metastatic colorectal cancer (CRC) who failed standard chemotherapy. Beijing Qiangxin Biotechnology Co. Ltd., Participated, in research.

  3. The Phase I clinical study of the dose-escalation tolerance and pharmacokinetics of AL58805 in the treatment of patients with advanced tumors Hangzhou Aidecheng Pharmaceutical Technology Co., Ltd. Participated, in research.

  4. A prospective one-arm exploration of the efficacy and safety of toiprizumab combined with oxaliplatin and tigio (SOX) in the first-line treatment of unresectable locally advanced, recurrent or metastatic gastric and gastroesophageal junction adenocarcinoma Clinical Research (IIT) Teriplizumab, Department of Oncology, Renji Hospital, Shanghai Jiaotong University School of Medicine, PI, finished.

  5. An open, multi-center phase II clinical study evaluating the Safety and Efficacy of BRAF inhibitor HLX208 with Cetuximab in metastatic Colorectal cancer with BRAF V600E Mutation after first-line treatment. PI, in research.


  • 2009.1~2011.12   Preliminary study of abnormal PI3K/AKT signaling pathway in colorectal cancer. Shanghai Municipal Bureau of Health (No.2008Y087)

  • 2012.1~2014.12   Anti-gastric cancer effects and molecular mechanism of LCA in vivo and vitro. National Natural Science Foundation of China Youth Fund Project (No: 81101648)

  • 2019.10~2021.09 Application of Micro-fluid Chip Based on EpCAM Antibody Recognition in Early Diagnosis and Efficacy Prediction of Gastric Cancer. Clinical Research Innovation Cultivation Fund Project of Shanghai Jiaotong University School of Medicine (No: PY2018-IIA-04)

  • 2021.10~2024.09 A clinical study based on the self-developed micro-fluid chip to detect circulating tumor cells to evaluate the efficacy of first-line drugs for advanced gastric cancer. Shanghai Science and Technology Commission Project (No: 21Y11913200)


  1. Wang Z#, Zhao S#, Lin X#, Chen G#, Kang J, Ma Z, Wang Y, Li Z*, Xiao X*, He A*, Xiang D*.Application of Organoids in Carcinogenesis Modeling and Tumor Vaccination. Front Oncol. 2022;12:855996.

  2. XL Lin#, T Han#, M Zhuo#, TF Liu, ZB Liu, DX Xiang*, H Li*,XY Xiao*, A retrospective study of clinicopathological characteristics and prognostic factors of Krukenberg tumor with gastric origin, J Gastrointest Oncol 2022;13(3):1022-1034

  3. XL Lin#, T Han#, Q Xia#, JJ Cui, Meng Zhuo, YY Liang, WY Su, LS Wang, LW Wang*,ZB Liu*,XY Xiao*. CHPF promotes gastric cancer tumorigenesis through the activation of E2F1. Cell Death Dis,2021;12(10):876.

  4. WX Liu#, ZY Zhan#, MY Zhang#, BW Sun, QQ Shi, F Luo, MDa Zhang, WW Zhang, YL Hou, XY Xiao*, YX Li*, HZ Feng*. KAT6A, a novel regulator of β-catenin, promotes tumorigenicity and chemoresistance in ovarian cancer by acetylating COP1. Theranostics. 2021;11(13):6278-6292

  5. Q Liu#, AQ Li#, LS Wang, W He, L Zhao, C Wu, SS Lu, XG Ye, HY Zhao, XH Shen, XY Xiao*, ZB Liu*. Stomatin-like Protein 2 Promotes Tumor Cell Survival by Activating the JAK2-STAT3-PIM1 Pathway, Suggesting a Novel Therapy in CRC. Mol Ther Oncolytics. 2020;17:169-179.

  6. Q Xia#, LY Zhao#, YD Yan#, Y Liao, YS Di, XY Xiao *. A Multiple Primary Malignancy Patient With FANCA Gene Mutation: A Case Report and Literature Review. Front Oncol. 2020 Jul 31;10:1199.

  7. Y Wang #, XY Xiao, T # Wang, Li L, Y Zhu, H Xu, Y Chu, F Jiao, J Cui, L Wang. A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma. J Cancer. 2018;9(7):1301-1307.

  8. XL Lin #, Q Xu #, L Tang, L Sun, T Han, LW Wang, XY Xiao *. Regorafenib inhibited gastric cancer cells growth and invasion via CXCR4 activated Wnt pathway. PLoS One. 2017;12(5):e0177335.

  9. XL Lin#, L Tian, LS Wang, WY Li, Q Xu, XY Xiao*. Antitumor effects and the underlying mechanism of licochalcone A combined with 5-fluorouracil in gastric cancer cells. Oncology Letter, 2017,13(3):1695-1701.

  10. Q Xu #, JL Tong, CP Zhang, Q Xiao, XL Lin, XY Xiao *, miR-27a induced by colon cancer cells in HLECs promotes lymphangiogenesis by targeting SMAD4. PLoS One. 2017;12(10):e0186718.

  11. CY Yin, XL Lin, L Tian, M Ye, XY Yang, XY Xiao*. Lobaplatin inhibits growth of gastric cancer cells by inducing apoptosis. World J Gastroenterol, 2014, 20(46): 17426-17433.

  12. XY Xiao#, LS Wang#, P Wei, YY chi, DL Li, QF Wang, SJ Ni, C Tan, WQ Sheng, MH Sun, XY Zhou, X du*. Role of MUC20 overexpression as a predictor of recurrence and poor outcome in colorectal cancer. Journal of Translational Medicine, 2013, 11: 151-151

  13. YF Zhu, BH Yu, DL Li, HL Ke, XZ Guo, XY Xiao*. PI3K expression and PIK3CA mutations are related to colorectal cancer metastases. World J Gastroenterol, 2012, 18(28): 3745-3751.

  14. LS Wang #, XY Xiao #, DL Li, YY Chi, P Wei; YQ Wang, SJ Ni, C Tan, XY Zhou, X Du*. Abnormal expression of GADD45B in human colorectal carcinoma. Journal of Translational Medicine, 2012, 10: 215-215.

  15. XY Xiao#, M Hao#, XY Yang, Q Ba, M Li, SJ Ni, LS Wang, X Du*. Licochalcone A inhibits growth of gastric cancer cells by arresting cell cycle progression and inducing apoptosis. Cancer Letters, 2011, 302(1): 69-75.

  16. XY Xiao#, XY Zhou, G Yan, MH Sun, X Du*. Chromosomal alteration in Chinese sporadiccolorectal carcinomas detected by comparative genomic hybridization. Diagn Mol Pathol, 2007, 16(2): 96-103.